A
fter months of controversy, the Colombian government has unilaterally lowered the price of a Novartis cancer drug by 44 percent, the latest step in a closely watched and particularly heated battle over access to medicines and intellectual property rights.
The move, which had been expected, comes after Colombian Health Minister Alejandro Gaviria issued a “declaration of public interest.” This allows the government to take various steps to reduce the price of a medicine, and Gaviria argued the price cut is justified because the cost for Gleevec is out of reach for some citizens.
Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!
SUBSCRIBE TODAYWhat is it?
STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.
What's included?
- Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
- Subscriber-only networking events and panel discussions across the country
- Monthly subscriber-only live chats with our reporters and experts in the field
- Discounted tickets to industry events and early-bird access to industry reports
About the Author
